ReviewMedical oncology (Northwood, London, England)2026
Folate-modified chitosan nanocarriers in precision oncology: molecular engineering, targeted drug delivery, and clinical perspectives.
Review in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a major cause of morbidity and mortality worldwide, and the effectiveness of conventional chemotherapy is frequently limited by poor tumor selectivity, systemic toxicity, rapid drug clearance, and multidrug resistance. These limitations have accelerated the development of targeted nanocarrier systems, with folate-functionalized chitosan nanoparticles (NPs) emerging as promising platforms for precision cancer therapy. Chitosan possesses favorable biocompatibility, biodegradability, mucoadhesive properties, and chemical versatility, while folate conjugation enables active targeting through folate receptor (FR)-mediated endocytosis. As FRs are overexpressed in several malignancies, including breast, ovarian, lung, colorectal, pancreatic, and cervical cancers, folate-functionalized NPs have the potential to enhance selective drug delivery, improve tumor accumulation, and minimize off-target toxicity. Recent advancements in smart and multifunctional nanocarriers, including MXene quantum dot polymer nanocomposites, have further emphasized the importance of surface engineering, multifunctionality, controlled drug release, and safety evaluation in the development of next-generation targeted drug delivery systems. Folate-functionalized chitosan NPs represent a biologically relevant and versatile class of targeted nanocarriers, offering the potential to enhance cellular uptake, provide sustained and controlled drug release, improve anticancer efficacy, and reduce systemic toxicity compared with non-targeted formulations. Important translational challenges, including reproducibility, formulation stability, interpatient variability in FR expression, immunogenicity, scalability, and regulatory considerations, also require careful attention for successful clinical development. Overall, this review provides a comprehensive overview of the design, synthesis, functionalization, therapeutic applications, pharmacokinetics, biodistribution, safety profiles, and clinical translation potential of folate-functionalized chitosan NPs for precision cancer therapy.
Indexed as
Identifiers
42742672What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.